Document is current
Any future updates will be listed below
-
Authors
Kohsaka, Shinji http://orcid.org/0000-0001-8651-6136
Yagishita, Shigehiro
Shirai, Yukina http://orcid.org/0009-0001-9196-9794
Matsuno, Yusuke
Ueno, Toshihide http://orcid.org/0000-0002-7408-7298
Kojima, Shinya
Ikeuchi, Hiroshi
Ikegami, Masachika
Kitada, Rina
Yoshioka, Ken-ichi
Toshimitsu, Kohta
Tabata, Kimiyo
Yokoi, Akira
Doi, Toshihiko
Yamamoto, Noboru
Owa, Takashi
Hamada, Akinobu
Mano, Hiroyuki http://orcid.org/0000-0003-4645-0181
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20pc0101051)
- License Information
-
More Information
Article History
Received: 27 November 2023
Accepted: 9 May 2024
First Online: 24 May 2024
Competing interests
: N.Y. reports research grants from Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, ONO, Janssen Pharma, MSD, MERCK, GSK, Sumitomo Dainippon, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, TORAY, KAKEN, InventisBio, and Rakuten Medical outside the submitted work as well as advisory fee from Eisai, Takeda, Boehringer Ingelheim, Cimic, and Chugai, and honoraria from ONO, Chugai, Daiichi-Sankyo, and Eisai outside the submitted work. K. Toshimitsu, K. Tabata, A.Y., and T.O. are Eisai employees.
